Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

ABSTRACT:

Objective

To report the 3-year follow-up results within a previously reported randomized trial evaluating prompt versus deferred (for ≥24 weeks) focal/grid laser treatment in eyes treated with intravitreal 0.5 mg ranibizumab for diabetic macular edema (DME).

Design

Multicenter, randomized clinical trial.

Participants

Three hundred sixty-one participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea.

Methods

Ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and random assignment to prompt or deferred (≥24 weeks) focal/grid laser treatment.

Main outcome measures

Best-corrected visual acuity and safety at the 156-week (3-year) visit.

Results

The estimated mean chang

SUBMITTER: Diabetic Retinopathy Clinical Research Network 

PROVIDER: S-EPMC3490003 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature